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ABSTRACT
In this study, we aimed to identify novel drivers that would be epigenetically 
altered through aberrant methylation in early-stage lung adenocarcinoma (LADC), 
regardless of the presence or absence of tobacco smoking-induced epigenetic field 
defects. Through genome-wide screening for aberrantly methylated CpG islands 
(CGIs) in 12 clinically uniform, stage-I LADC cases affecting six non-smokers and 
six smokers, we identified candidate tumor-suppressor genes (TSGs) inactivated 
by hypermethylation. Through systematic expression analyses of those candidates 
in panels of additional tumor samples and cell lines treated or not treated with 
5-aza-deoxycitidine followed by validation analyses of cancer-specific silencing by 
CGI hypermethylation using a public database, we identified TRIM58 as the most 
prominent candidate for TSG. TRIM58 was robustly silenced by hypermethylation 
even in early-stage primary LADC, and the restoration of TRIM58 expression in 
LADC cell lines inhibited cell growth in vitro and in vivo in anchorage-dependent and 
-independent manners. Our findings suggest that aberrant inactivation of TRIM58 
consequent to CGI hypermethylation might stimulate the early carcinogenesis of LADC 
regardless of smoking status; furthermore, TRIM58 methylation might be a possible 
early diagnostic and epigenetic therapeutic target in LADC.
INTRODUCTION
Lung adenocarcinoma (LADC) is the most 
predominant histologic subtype of lung cancer and one 
of the leading causes of cancer-related death worldwide 
[1, 2]. Although major improvements in treatment 
strategies have increased the short-term survival of 
patients with LADC, the impacts on long-term survival 
have remained modest [3]. Both late diagnosis and the 
scarcity of therapies that effectively achieve durable 
responses are important factors associated with poor 
outcomes. A better understanding of the molecular 
pathogenesis of LADC is needed to identify biomarkers 
that could be useful for early detection and to develop 
novel targeted therapies. 
Aberrant promoter CpG island (CGI) methylation 
of tumor suppressor genes (TSGs) has been established 
as a common epigenetic mechanism underlying the 
pathogenesis of human cancers, including LADC 
[4, 5]. DNA methylation is a stable modification that often 
occurs at an early stage of carcinogenesis; as a result, 
such events are sensitive and specific biomarkers, even 
in tumor samples contaminated by non-tumorous cells as 
well as various biological fluids used for liquid biopsies. 
In LADC, distinct interactions between genetic and 
epigenetic changes were found to contribute differently 
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to carcinogenesis in smokers (S) vs. never smokers (NS) 
[6, 7]. However, few genes that are altered by aberrant 
DNA methylation irrespective of etiology (particularly 
smoking status) and contribute to early LADC 
carcinogenesis have been identified.
In the present study, we performed a systematic, 
genome-wide screening of aberrantly methylated CGIs 
in stage-I LADCs from both S and NS to identify genes 
commonly dysregulated via aberrant DNA methylation 
in early-stage LADC, regardless of smoking status. 
To this end, we applied a series of criteria that targeted 
novel genes frequently silenced in LADC tumors and cell 
lines (possibly through hypermethylation) to prioritize 
the selection of top candidates for validation. TRIM58, 
a subsequently identified candidate, showed frequent 
CGI hypermethylation and its inverse relationship with 
gene expression in a larger set of LADC tumors and cell 
lines, followed by validation using a data set obtained 
from The Cancer Genome Atlas (TCGA). In addition, 
our functional analyses demonstrated the ubiquitin-ligase 
activity-dependent growth suppressive effect of TRIM58 
on LADC cells both in vitro and in vivo, suggesting that 
this gene exerts TSG during the initiation and/or early 
progression stages of LADC.
RESULTS
Screening of aberrantly methylated and silenced 
genes from the early stage of LADC 
We initially screened tumors and paired non-
tumorous tissues obtained from 12 male patients with 
stage-I LADC (6 S, 6 NS; Table 1) using an Illumina 
HumanMethylation450K BeadChip to identify 
differentially methylated CGIs in a genome-wide manner 
(Figure 1A). Because the number of hypermethylated 
CGIs was much larger than that of hypomethylated CGIs 
(Figure 1B), we focused on the former group. A total of 
113 CGIs were identified as differentially hypermethylated 
CGIs, with a false discovery rate (FDR) of < 0.05 and β 
difference (tumor − non-tumorous tissue) of > 0.25. 
Next, we determined the mRNA expression of 
9 genes associated with the top 10 CGIs (Table 2) in 
commercially available normal lung, panels of 11 stage-I or 
-II LADC cases (Supplementary Table S1), and 14 LADC 
cell lines via quantitative reverse-transcription polymerase 
chain reaction (qRT-PCR). Differential hypermethylation 
in tumors of those genes except MEIS2 was validated 
using 29 paired cases of a TCGA data set (Supplementary 
Table S2). Three genes (DDX25, FEZF2, and C12orf42) 
that exhibited no or very low expression in commercially-
available normal lung and non-tumorous lung tissues (data 
not shown) as well as 58 non-tumorous lung tissues from 
the TCGA data set (Supplementary Figure S1). Three 
genes (ZNF577, MEIS2, and PTPRN2) were infrequently 
downregulated in LADC tumors relative to paired 
non-tumorous tissues and/or LADC cell lines compared 
with normal lung (Supplementary Figures S2 and S3). The 
TCGA data set validated significant but small reductions 
in the expression levels of these genes in tumors relative to 
non-tumorous tissues (Supplementary Table S2). 
Finally, we conducted pharmacological re-expression 
experiments in LADC cell lines treated with vehicle, 5-aza-
2′-deoxycitidine (5-aza-dC) and/or trichostatin A (TSA). 
Only TRIM58 restoration was effectively (log2(fold change) 
> 2) and consistently (3/3 lines) observed throughout 5-aza-
dC treatment (Figure 1E and Supplementary Figure S4A). 
In addition, the effect of 5-aza-dC treatment on TRIM58 
expression was not observed in TRIM58-expressing cell 
lines (Supplementary Figure S4B). Accordingly, TRIM58 
was identified as the most likely candidate for DNA 
methylation-induced silencing from the early stages of 
LADC, irrespective of smoking status. Decreased TRIM58 
mRNA expression in tumors relative to paired non-
tumorous tissues was consistently observed even after the 
inclusion of 27 additional cases with various stages and 
smoking statuses (Figure 1C).
Expression and CGI methylation status at the 
TRIM58 promoter in LADC
Using methylation array data of 12 stage-I cases, 
we analyzed details regarding the methylation status of 
CpG sites around TRIM58. CpG sites within the CGI 
exhibited low levels of methylation (β value = 0.1–0.2) 
in non-tumorous tissues and significantly higher levels in 
paired tumors (Figure 2A), irrespective of the patient’s 
smoking status (Supplementary Figure S5A). Identical 
results were obtained in the TCGA data set (n = 29, 
Supplementary Figure S5B). 
Because almost all clinical cases exhibited 
decreased TRIM58 expression, the correlation between 
the CGI methylation status and TRIM58 expression status 
was first assessed in LADC cell lines (Figures 1D and 2B). 
Quantitative pyrosequencing analysis of five target CpG 
sites within the TRIM58 CGI revealed low methylation 
levels in most CpG sites in all three LADC cell lines with 
higher-than-normal TRIM58 expression levels, whereas 
cell lines with very low TRIM58 expression (except 
RERF-LC-KJ) exhibited high levels of methylation, 
particularly at cg20429172 (target III) and cg26157385 
(target IV). In three 5-aza-dC-treated cell lines with 
restored TRIM58 mRNA expression, the methylation 
levels decreased to some extent at all target sites. 
The methylation statuses of CpG sites within the 
TRIM58 CGI around cg20429172 and cg26157385 were 
confirmed by bisulfite sequencing in TRIM58-expressing 
(RERF-LC-MS) and TRIM58-nonexpressing (NCI-H358) 
cells treated or not with 5-aza-dC (Figure 2C). A promoter 
reporter assay using various DNA fragments overlapped 
with the CGI in both TRIM58-expressing and non-
expressing cell lines demonstrated that only fragments 
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2 and 4 containing cg20429172 and cg26157385 exhibited 
significant promoter activity regardless of the endogenous 
TRIM58 expression status (Figure 2D), suggesting that the 
methylation of cis-regulatory CpG sites within fragment 4 
most likely determines, at least in part, the TRIM58 mRNA 
expression level. 
Using normalized RNA-seq gene expression data 
and HumanMethylation450K BeadChip data of 17 LADC 
tumors and paired non-tumorous tissues from the TCGA 
data set, we confirmed an inverse correlation between 
the TRIM58 expression and methylation levels at five 
pyrosequencing target sites (Supplementary Figure S5C). 
At those sites, particularly cg20429172 and cg26157385, 
mutually exclusive plotting of the expression and 
methylation levels was observed between tumors and non-
tumorous tissues. In a larger set of our LADC cases (46 
cases), pyrosequencing demonstrated the smoking status-
independent, consistent tumor-specific hypermethylation 
of cg26157385 (Figure 3A). 
To evaluate the TRIM58 protein expression status 
in LADC tumors and paired non-tumorous lung tissues, 
immunohistochemical staining (IHC) was performed 
(Figure 3B). In non-tumorous lung tissues, cytoplasmic 
TRIM58 staining was observed in alveolar epithelial 
cells, especially type II cells, whereas almost no TRIM58 
staining was observed in LADC tumor cells, irrespective 
of the smoking status and tumor stage.
TRIM58 overexpression suppresses LADC cell 
proliferation and tumor formation in vitro and  
in vivo
To investigate the biological significance of TRIM58 
in the carcinogenesis of LADC, TRIM58 expression was 
transiently or stably restored in LADC cells lacking its 
endogenous expression. Because TRIM58 was silenced 
in most LADC cases even at early stages, we evaluated 
proliferation and tumor formation in those cells both 
in vitro and in vivo. TRIM58 is a member of the tripartite 
motif (TRIM)-containing protein family, which mainly 
comprises E3 ubiquitin (Ub) ligases containing a RING-
finger domain with E3 Ub ligase activity. To determine 
whether the effects of TRIM58 depend on its Ub ligase 
activity, we simultaneously assessed a wild-type TRIM58 
(TRIM58-WT) and a mutated form that lacked poly-
ubiquitination activity consequent to a switch of histidine 
33 to alanine within the RING-finger domain (TRIM58-
Mut, Figure 4A) with the control counterparts (empty 
vector transfectants).
In colony-formation assays involving transiently 
transfected cells, fewer colonies were produced by 
TRIM58-WT-transfected LADC cell lines when compared 
to control and TRIM58-Mut-transfected cells (Figure 4B). 
In an in vitro proliferation assay of stably transfected 
cells, cells expressing exogenous TRIM58-WT protein 
(predominant cytoplasmic location) grew significantly 
more slowly than mock-transfected controls and TRIM58-
Mut-expressing cells (Figure 5A). Notably, p21 expression 
was pronounced only in TRIM58-WT-overexpressing 
cells, whereas a minimal effect of TRIM58-WT 
overexpression on PARP cleavage was observed in A549 
cells and no effect on PARP cleavage was observed in 
HCC827 cells (Figure 5B). In a flow-assisted cell sorting 
(FACS) analysis in A549 cells to examine the mode of 
action of TRIM58 within the cell cycle, we observed an 
accumulation of cells in G0-G1 phase and decreases in cells 
in the S and G2-M phase without an increase in sub-G1 
phase cells among TRIM58-WT-transfected cells relative 
Table 1: Clinicopathological characteristics of patients with LADC analyzed by Infinium 
HumanMethylation450K BeadChips
ID Age (yrs) Gender Smoking status Pack-years
Tumor
TNM classification Stage Size (mm)
S1 68 Male Smoker 1000 pT1aN0M0 Ia 13 × 11
S2 80 Male Smoker 1200 pT1aN0M0 Ia 14 × 11
S3 60 Male Smoker 1020 pT2aN0M0 Ib 17 × 11
S4 59 Male Smoker 1600 pT1aN0M0 Ia 13 × 10
S5 74 Male Smoker 2400 pT1aN0M0 Ia 12 × 11
S6 75 Male Smoker 1000 pT1aN0M0 Ia 25 × 20
NS1 77 Male Never smoker 0 pT1aN0M0 Ia 20 × 13
NS594 74 Male Never smoker 0 pT1aN0M0 Ia 19 × 17
NS3 57 Male Never smoker 0 pT1aN0M0 Ia 15 × 15
NS4 73 Male Never smoker 0 pT2aN0M0 Ib 42 × 19
NS5 51 Male Never smoker 0 pT1aN0M0 Ia 14 × 9
NS6 68 Male Never smoker 0 pT1aN0M0 Ia 13 × 11
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Figure 1: TRIM58 was identified as a candidate in a screening of genes silenced through hypermethylation of the CpG 
islands (CGI) in lung adenocarcinomas (LADCs) from an early stage, regardless of patient smoking status. (A) Flow 
chart indicating the study design, which aimed to identify candidate tumor suppressor genes using experimental and bioinformatic filters. 
(B) Volcano plot of the differential CGI methylation statuses of 12 stage-I LADC tumors and paired non-tumorous tissues. The x-axis 
indicates the average difference in β-value (methylation level), and the y-axis indicates the–log10 of the adjusted P-value for each CGI. The 
arrow indicates the CGI around TRIM58. (C) Relative expression (fold change) of TRIM58 mRNA in tumor tissues vs. paired non-tumorous 
tissues in a panel of LADC cases (n = 38 including 18 smokers [S] and 20 non-smokers [NS]; Supplementary Table S1) evaluated by qRT-
PCR. Expression data were normalized to GAPDH (means ± standard deviations [SD] of triplicate experiments). Asterisks indicate 11 cases 
used to screen candidate gene expression (Supplementary Figure S2); arrowheads indicate cases used for array-based methylation screening 
(see Table 1). Dotted line indicates 0.5. (D) Expression levels of TRIM58 mRNA (upper) and protein (lower) in LADC cell lines. Upper, 
relative expression levels of TRIM58 mRNA in 14 LADC cell lines vs. normal lung tissues; expression was evaluated using qRT-PCR and 
normalized to GAPDH. Dotted line indicates 0.2. Lower, TRIM58 protein expression in five cell lines was determined by western blotting 
with a TRIM58-specific antibody. (E) Effect of treatment with 5-aza-dC and/or TSA on TRIM58 mRNA expression in three LADC cell 
lines. The expression levels of TRIM58 mRNA, which were evaluated by qRT-PCR and normalized to GAPDH, are shown relative to those 
of vehicle-treated control cells (means ± SDs of triplicate experiments). Dotted line indicates four (fold change).
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Figure 2: Correlation of CpG site methylation with the TRIM58 expression status in lung adenocarcinoma (LADC) 
cell lines. (A) A schematic diagram of the TRIM58 gene structure and CpG sites around exon 1 (middle), the average β-value (methylation 
level) of each CpG site targeted in the array-based methylation experiment involving 12 LADC cases (upper), and the CpG sites around 
exon 1 and the CpG island (CGI) with CpG sites targeted by pyrosequencing (arrowhead, I–V), as well as the regions analyzed via 
bisulfite sequencing (closed arrows, regions 1–3) and promoter assays (horizontal bar, segments 1–6). *P < 0.05 vs. paired non-tumorous 
tissue. (B) Average DNA methylation values, shown as percentages from quantitative pyrosequencing to analyze five target sites in 14 cell 
lines, including three cell lines treated with 5-aza-dC (triplicate experiments). Results were classified into five grades according to 20% 
quintiles. Cells were divided into three groups according to the expression of TRIM58 mRNA relative to the normal lung: H, ≥ normal lung; 
M, < normal lung but ≥ 20% of the normal lung; L, < 20% of the normal lung. (C) Bisulfite sequencing of part of the TRIM58 CGI 
(see Figure 2A) in RERF-LC-MS, NCI-H358, and 5-aza-dC-treated NCI-H358 cells. Open and filled squares represent unmethylated and 
methylated CpG sites, respectively, and each row represents the results for a single clone. Arrowheads, target sites for pyrosequencing. 
(D) Luciferase assays involving pGL3 constructs containing various fragments around the TRIM58 CGI (see Figure 2A) in TRIM58 non-
expressing and expressing LADC cell lines (see Figure 1D). Values are expressed as the fold activation relative to pGL3-mock transfected 
cells (means ± standard deviations of three independent experiments). 
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to mock-transfected or TRIM58-Mut-transfected cells 
(Figure 5C). Similar results were obtained in HCC827 
cells (Supplementary Figure S6), suggesting that wild-
type TRIM58 contributes mainly to the arrest of LADC 
cells at the G1-S checkpoint probably through its Ub ligase 
activity. In addition, anchorage-independent in vitro 3D 
cell proliferation, determined via spheroid formation in 
low-attachment wells (Figure 5D) and colony formation 
in soft agar (Figure 5E), was also inhibited in TRIM58-
WT-transfected A549 cells relative to mock-transfected or 
TRIM58-Mut-transfected counterparts. 
The ability of TRIM58 to suppress tumor 
formation in vivo was investigated using tumor xenograft 
experiments in which subcutaneous tumor growth was 
compared among severe combined immunodeficient 
(SCID) mice transplanted with different stable A549 
transfectants. Restored expression of TRIM58-WT in 
A549 cells was associated with a reduced tumor volume 
and weight in vivo (Figure 6A, 6B, and Supplementary 
Figure S7). This outcome was attributed to a decrease 
in anchorage-dependent and/or -independent cell 
proliferation, as demonstrated by reduced Ki-67 positivity 
in TRIM58-WT-transfected cells relative to mock-
transfected or TRIM58-Mut-transfected cells in resected 
tumors (Figure 6C).
Very recently, TRIM58 was found to facilitate 
erythroblast enucleation by interfering with the 
established ability of dynein to regulate intracellular 
Table 2: Top 10 CpG islands significantly hypermethylated in tumors compared to paired non-
tumorous tissues of 12 stage-I LADC cases
Methylation status of 
CpG island
CpG island-related 
RefSeq genea Expression status of CpG island-related gene
b
Rank CpG island Adjusted P-valuec β-difference
d Gene 
name
Location 
of CpG 
islande
Expression 
in normal 
lungf
Low 
expression 
in tumors of 
early LADC 
casesg
Low 
expression 
in LADC 
cell linesh
Restration of 
expression in 
5-aza-dC-treated 
LADC cell linesi
1 chr7:153583317–153585666 2.92E−05 0.2776 DPP6 Exon 1 Yes 8/11 14/14 1/3
2 chr11:125774292–125774584 3.04E−05 0.2719 DDX25 Exon 1 Very low − − −
3 chr19:52390841–52391368 3.04E−05 0.2915 ZNF577 Exon 1 Yes 6/11 10/14 0/3
4 chr3:62355315–62355534 3.24E−05 0.2589 FEZF2 Gene body Very low − − −
5 chr1:156863415–156863711 3.26E−05 0.3692 PEAR1 Exon 1 Yes 5/11 14/14 0/3
6 chr15:37390175–37390380 3.81E−05 0.3249 MEIS2 Gene body Yes 4/11 3/14 1/3
7 chr1:248020330–248021252 5.10E−05 0.2703 TRIM58 Exon 1 Yes 10/11 (36/37) 10/14 3/3
8 chr3:62362610–62363082 5.44E−05 0.2521 FEZF2 Upstream − − − −
9 chr12:103696090–103696418 5.70E−05 0.3189 C12orf42 Gene body Very low − − −
10 chr7:158110569–158110881 6.58E−05 0.2702 PTPRN2 Gene body Yes 3/11 7/14 2/3
aRefSeq gene (http://www.ncbi.nlm.nih.gov/refseq/) located on or around each CpG island was selected as CpG island-related gene.
bExpression status was evaluated in 9 genes, because two CpG islands located on one gene (FEZF2).
cDifferences between methylation levels (β-values) of CpG islands in tumors and paired non-tumorous tissues were assessed by paired t-test. P-values were 
adjusted with the Benjamini-Hochberg correction (False discovery rate, FDR). CpG islands were sorted by adjusted P-value.
dβ-differences (differential methylation levels) represent the average of [(β-value of tumorous tissue) - (β-value of paired non-tumorous tissue)] in 12 stage-I 
LADC cases.
eExon 1, CpG island locates within or contains exon 1 of gene; gene body, CpG island locates within or around exons other than exon 1 or introns; upstream, 
CpG island locates upstream of exon 1. 
fVery low, expression level was undetermined by qRT-PCR in normal lung tissue (Clontech) and non-tumorous lung tissues in 11 cases with LADC. 
gLow expression, > 50% reduction of relative gene expression level in tumors compared with paired non-tumorous tissues of early LADC cases. The boldface 
shows frequently (≥ 6/11 cases) silenced genes.  
hLow expression, > 80% reduction of relative gene expression level in cell lines compared with the normal lung tissue (Clontech). The boldface shows 
frequently (≥ 8/14 cases) silenced genes.  
iRestoration of expression, a > 4-fold (Log2 > 2 fold) increase in mRNA expression in 5-aza-dC-treated cells compared to paired vehicle-treated cells (control). 
The boldface shows frequently (≥ 2/3 cell lines) restored genes.  
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nuclear positioning and/or microtubule structures during 
erythropoiesis [8]. However, the molecular mechanisms 
underlying the tumor-suppressive function of TRIM58 
remain unknown and might be different from those 
involved in erythropoiesis. Indeed, our preliminary 
analysis demonstrated a lack of significant changes in the 
protein expression levels of dynein heavy chain 1 (DHC1) 
and intermediate chains (DIC), which were reported to be 
possible substrates of TRIM58 in proteasome-dependent 
degradation [8] between TRIM58-WT-overexpressing 
cells and mock-transfected or TRIM58-Mut-transfected 
counterparts (Supplementary Figure S8). To better 
elucidate the molecular mechanisms of tumor suppression 
by TRIM58, we performed microarray analysis to 
determine the effects of stable TRIM58 overexpression 
on the A549 cell transcriptome. We identified 1,889 
Figure 3: CpG site methylation and TRIM58 expression status in primary lung adenocarcinoma (LADC) tumors 
and paired non-tumorous tissues. (A) Average DNA methylation values (percentages) of cg26157385 (target IV, see Figure 2A) 
in 46 LADC tumors and paired non-tumorous tissues from 25 smokers (S) and 21 nonsmokers (NS), as determined by quantitative 
pyrosequencing. Samples from the same patient are linked with dotted or straight lines. (B) Representative images of immunohistochemical 
staining for TRIM58 in LADC tumors and adjacent non-tumorous lung tissues. S and NS indicate smokers and nonsmokers, respectively. 
Scale bars, 200 μm.
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Figure 4: Suppressive effects of transiently transfected TRIM58 on the proliferation of lung adenocarcinoma (LADC) 
cells in vitro. (A) Ubiquitin activities of wild-type and mutant TRIM58 were determined by detecting the autoubiquitination of TRIM58 
proteins exogenously expressed in HEK293 cells. Cells were transiently transfected with MYC-tagged Ub and pCMV-3Tag1A (mock), 
pCMV-3Tag1A-wild-type TRIM58 (TRIM58-WT), or pCMV-3Tag1A-mutant TRIM58 (TRIM-Mut), cultured for 40 h, and treated with 
50 μM MG132 or vehicle (DMSO) for 8 h. Cell lysates were immunoprecipitated with an anti-FLAG antibody and blotted using antibodies 
specific for FLAG (upper) or MYC (lower). (B) LADC cell lines transfected with pCMV-3Tag1A (mock), pCMV-3Tag1A-wild-type 
TRIM58 (TRIM58-WT), or pCMV-3Tag1A-mutant TRIM58 (TRIM58-Mut) were plated in 6-well plates and treated with 0.5 mg/mL G418 
for two weeks. FLAG-tagged TRIM58 expression was confirmed by western blotting with an anti-FLAG antibody (upper). Drug-resistant 
colonies were stained with crystal violet and counted (middle). Columns, means ± standard deviations of four independent experiments 
(lower). *P < 0.05 versus mock control, Welch’s t-test.   
Oncotarget2898www.impactjournals.com/oncotarget
Figure 5: Suppressive effects of stably restored TRIM58 expression on the proliferation of lung adenocarcinoma 
(LADC) cells in vitro. (A) Left, representative images of A549 or HCC827 cells engineered to stably express FLAG-tagged exogenous 
wild-type TRIM58 (TRIM58-WT) or mutant TRIM58 (TRIM58-Mut), detected by FIC with an anti-FLAG antibody (green). Nuclei were 
counterstained with DAPI (blue). Scale bars, 20 μm. Right, numbers of viable cells for each stable transfectant were assessed using a 
WST assay for the indicated times. Values are expressed as fold changes (mean ± standard deviation [SD], n = 8) relative to the respective 
control values (24 h). a,b,c,d P < 0.05 compared with the A549 mock#1, mock#2, TRIM58-Mut#1, and TRIM58-Mut#2 clones, respectively, 
at 96 h after plating. e,f P < 0.05 compared with the HCC827 crude mock and TRIM58-Mut transfectants, respectively, at 96 h after plating. 
(B) Levels of PARP, p21, and exogenous TRIM58 protein expression in each stable transfectant were analyzed by western blotting, using 
GAPDH as a loading control. (C)Representative results of the population in each phase of the cell cycle in A549 stable transfectants 
assessed by a FACS analysis. (D) Spheroid formation assay. A549 stable transfectants were seeded in ultra-low attachment 96-well round 
bottom plates and incubated at 37°C for seven days. Areas of the resulting spheroids were determined as described in the Materials and 
Methods section (mean ± SD, n = 8). a,b,c,d P < 0.05 compared to A549 mock#1, mock#2, TRIM58-Mut#1, and TRIM58-Mut#2 clones, 
respectively. (E) Colony formation assay in soft agar. A549 stable transfectants were cultured in semi-solid medium for 26 days as described 
in the Materials and Methods section (mean ± SD, n = 3). 
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probes for differentially expressed genes (DEGs) based 
on the criteria of a 2-fold change and an adjusted P-value 
< 0.05; specifically, 1036 and 853 probes were significantly 
upregulated and downregulated, respectively, in TRIM58-
WT-overexpressing cells relative to mock control cells. 
To further identify significantly overrepresented Gene 
Ontology (GO) terms affected by TRIM58 expression in 
A549 cells, those DEGs were analyzed using The Database 
for Annotation, Visualization, and Integrated Discovery 
(DAVID) v6.7 software [9,10]. Among the DEGs, 1562 
genes (796 increased genes and 766 decreased genes) 
were mapped in the DAVID database. After applying a 
functional annotation clustering algorithm to reduce 
annotation redundancy, the GO analysis revealed a 
highly significant change in the expression of genes 
encoding proteins involved in the extracellular region 
(Cluster 1, enrichment score 7.29), extracellular matrix 
(ECM)/basement membrane (Cluster 2, enrichment score 
7.15), and cell adhesion/cell-cell adhesion (Cluster 3, 
enrichment score 5.58), suggesting that TRIM58 might 
contribute to cell-cell and/or cell-ECM adhesion (Table 3, 
Supplementary Table S3). 
DISCUSSION
To our knowledge, this study is the first to 
demonstrate the functional significance of TRIM58 as a 
TSG in the context of tumorigenesis. In both our panel of 
LADC cases and a publicly available data set (TCGA), 
TRIM58 was consistently silenced via hypermethylation 
in a tumor-specific manner even in the early stages 
of tumorigenesis and regardless of smoking status. In 
addition, the restoration of TRIM58 expression in LADC 
cells inhibited the growth of LADC cells in vitro and 
in vivo through its Ub ligase activity. Although the Ub 
ligase target substrates that underlie the tumor suppressive 
activity of TRIM58 remain unknown, this activity appears 
to associate with cell-cell and/or cell-ECM adhesion, 
suggesting that the inactivation of TRIM58 might 
contribute to the epithelial disintegration observed in early 
carcinogenesis. Taken together, these findings indicate that 
TRIM58 likely acts as a TSG in the early stages of lung 
carcinogenesis, such as initiation or early tumorigenesis 
regardless of smoking-induced “field defects.” Indeed, the 
TRIM58 CGI methylation levels in non-cancerous lung 
Table 3: Partial list of the enriched gene ontology clusters based on the set of differentially expressed 
genes in TRIM58-overexpressed A549 cells
Annotation Cluster 1 Enrichment Score: 7.29
Category Term Gene count P-Valuea Adjusted P-valueb
GOTERM_CC_FAT extracellular region part 133 1.0E–10 4.8E–08
GOTERM_CC_FAT extracellular region 224 2.4E–08 3.8E–06
GOTERM_CC_FAT extracellular space 84 5.5E–05 1.6E–03
Annotation Cluster 2 Enrichment Score: 7.15
Category Term Gene count P–Valuea Adjusted P–valueb
GOTERM_CC_FAT extracellular region part 133 1.0E–10 4.8E–08
GOTERM_CC_FAT extracellular matrix 64 2.4E–10 5.7E–08
SP_PIR_KEYWORDS extracellular matrix 47 8.1E–09 1.7E–06
GOTERM_CC_FAT proteinaceous extracellular matrix 56 3.1E–08 3.7E–06
SP_PIR_KEYWORDS basement membrane 14 3.9E–06 6.0E–04
GOTERM_CC_FAT extracellular matrix part 25 1.3E–05 5.9E–04
GOTERM_CC_FAT basement membrane 19 2.9E–05 1.1E–03
Annotation Cluster 3 Enrichment Score: 5.58
Category Term Gene count P–Valuea Adjusted P–valueb
GOTERM_BP_FAT biological adhesion 99 6.6E–08 8.1E–05
GOTERM_BP_FAT cell adhesion 98 1.2E–07 7.3E–05
SP_PIR_KEYWORDS cell adhesion 60 5.9E–06 6.1E–04
GOTERM_BP_FAT cell-cell adhesion 39 9.9E–04 4.5E–02
aP-values were obtained by loading all differentially expressed genes (adjusted P-value < 0.05, upregulated and downregulated 
genes with > 2-fold changes) into DAVID Functional Annotation Clustering Tool (https://david.ncifcrf.gov/) to reduce 
annotation redundancy.
bP-values were adjusted with the Benjamini-Hochberg correction.
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tissues of S and NS were similar ( Figure 2E), suggesting 
that TRIM58 may be a universal epigenetic early 
diagnostic marker, rather than a prognostic marker, of 
LADC, and may also serve as a possible preventive and/or 
therapeutic target through the epigenetic restoration of its 
expression. Further analyses of the direct Ub-ligase targets 
involved in the TRIM58-activated tumor suppressive 
pathway are needed to identify alternative preventive and/
or therapeutic strategies for LADC.
The frequent inactivation of TRIM58 via 
hypermethylation observed even in early-stage cases from 
our panel of primary LADC cases was consistent with 
Figure 6: Suppressive effects of restored TRIM58 expression on the formation of A549 cell tumors in vivo. (A) Tumor 
growth was assessed weekly for up to 28 days after the injection of Matrigel suspensions of each A549 stable transfectant into the flanks 
of severe combined immunodeficient (SCID) mice. Tumor volumes (mm3) were calculated as described in the Materials and Methods 
section. Time-dependent changes in tumor masses are shown (mean ± standard deviation [SD], n = 3). a,b P < 0.05 compared to mock#1 and 
mock#2, respectively. (B) The SCID mice used in Figure 6A were sacrificed to evaluate tumor weights on day 28 after inoculation. Mean 
± SD tumor weights are shown (n = 3). a,b P < 0.05 compared to mock#1 and mock#2, respectively. (C) Representative tumors formed in 
SCID mice on day 28 after inoculation (left) and immunohistochemical analysis of FLAG-tagged TRIM58 protein (wild-type or mutant) 
and Ki-67 expression (right). Bars, 100 μm.
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the findings of a very recent report [11] in which Diaz-
Lagares et al. identified TRIM58 as one of four genes that 
consistently exhibited CGI hypermethylation in non-small 
cell lung cancers (NSCLCs) relative to non-malignant 
lung tissues. In addition, Diaz-Lagares and colleagues 
found that this hypermethylation was associated with 
transcriptional silencing in early-stage (stage I) NSCLCs, 
regardless of smoking status, and identified a DNA 
methylation signature model based on those four genes 
that yielded high diagnostic accuracy for NSCLCs even 
in minimally invasive samples, such as bronchial fluids 
[11]. According to reference databases in which gene 
expression profiles of normal tissue have been generated 
using next-generation RNA sequencing technologies, such 
as RNA-seq Atlas (http://medicalgenomics.org/rna_seq_
atlas) and RefEx (http://refex.dbcls.jp/), TRIM58 mRNA 
was not detected in most normal tissues although higher 
expression of this gene is observed in the lung relative 
to the levels in various other tissues. Very recently, 
hypermethylation was found to correlate with decreased 
TRIM58 expression in hepatocellular carcinoma (HCC) 
cells relative to paired adjacent liver tissues, although 
no functional characterization was observed in HCC 
cells [12]. Given the infrequency of TRIM58 CGI 
hypermethylation (28.18%, 51/181 cases) and tendency 
of this event to correlate with unfavorable disease-free 
survival in HCC [12], hypermethylation appears to occur 
in more progressive HCC tumors. Therefore, it remains 
unclear whether TRIM58 plays different tumor suppressive 
roles in the lung and liver.
The prevalence of CGI/promoter methylation 
in lung cancers, including LADC, has been reported to 
differ between S and NS; specifically, higher methylation 
of CDKN2A, MGMT, RASSF1, MTHFR, and FHIT 
promoters has been observed in S vs. NS, whereas 
RASSF2, TNFRSF10C, BHLHB5, and BOLL methylation 
is more common in NS than in S [13]. In the present study 
of LADC, we conducted a genome-wide screen to identify 
novel driver genes that contribute to early carcinogenesis 
following aberrant CGI methylation and consequent 
epigenetic activation or inactivation, regardless of the 
presence or absence of epigenetic field defects caused by 
tobacco smoking, in 12 clinically uniform stage-I LADC 
cases. Of the nine genes clustered around the top 10 
hypermethylated CGIs in tumors, several were reported to 
serve as epigenetic markers of DNA hypermethylation in 
various malignant diseases, including LADC [9, 14–18]; 
however, previously described well-known methylation 
targets in lung cancers [13] were not included in this 
list. For example, PTPRN2 hypermethylation changes 
had been previously reported in LADC, even in pre-
neoplastic lesions or atypical adenomatous hyperplasias 
[14]. Frequent methylation of PTPRN2 and ZNF577 
were reported in lung squamous cell carcinomas [15,16]. 
FEZF2 was found to be a 3p14 TSG that is frequently 
methylated in nasopharyngeal squamous cell carcinoma 
[17]. However, the effects of hypermethylation on the 
expression of these three genes in LADC cases were 
small or even opposite to the effects reported in the TCGA 
data set. In addition, FEZF2 was not expressed in normal 
lung tissues. Furthermore, silencing of DPP6 through 
hypermethylation of its promoter was reported in acute 
myeloid leukemia [18] and an in vitro neuronal differential 
model [19], whereas hypomethylation and subsequently 
increased expression of this gene have been found in 
colon cancer [20], suggesting that the tumor suppressive 
role of this gene in epithelial tumors remains unknown. 
Taken together, the biological significance of selected 
candidate genes as molecular targets for epigenetic 
modification therapy of LADC remains unclear, with the 
exception of TRIM58. However, the methylation statuses 
of these genes, which were validated in the TCGA data set 
except for MEIS1 and PTPRN2, might be useful as early 
molecular diagnosis markers of LADC. 
MATERIALS AND METHODS
Primary tissue sample collection
In total, 76 paired tumor/non-tumorous LADC 
sample sets were obtained from patients (39 S, 37 NS) 
with histologically proven primary LADC who underwent 
surgery at Tokushima University Hospital (Tokushima, 
Japan) between April 1999 and March 2015. None of the 
patients had received preoperative radiation, chemotherapy, 
or immunotherapy. A total of 12 LADC (6 S and 6 NS), 
46 LADC (25 S and 21 NS), 38 LADC (18 S and 20 
NS), and 63 LADC sets (28 S and 35 NS) were used for 
methylation screening with a HumanMethylation450K 
array, pyrosequencing-based methylation analysis, real-
time PCR-based expression analysis, and IHC, respectively 
(Table 1, Supplementary Table S1). 
Tumors were snap-frozen in liquid nitrogen 
and stored at −80°C until required for DNA and RNA 
analyses. Tumor specimens were characterized according 
to the International System of Classification of Tumors, 
which was based on the tumor-node-metastasis (TNM) 
classification of the IASLC Lung Cancer Staging 
Project (7th edition) [21]. Diagnoses were verified by 
histopathology, and only samples with at least 70% tumor 
cells were used in the study. 
This study was performed in accordance with the 
principles outlined in the Declaration of Helsinki. Following 
the approval of all aspects of these studies by the local ethics 
committee (Tokushima University Hospital, approval number 
2204), formal written consent was obtained from all patients. 
DNA and RNA preparation and bisulfite 
conversion of genomic DNA 
DNA and RNA were extracted using standard 
methods. Bisulfite conversion of DNA was conducted 
Oncotarget2902www.impactjournals.com/oncotarget
using the EZ DNA Methylation Gold Kit (Zymo Research, 
Orange, CA, USA).
Global methylation analysis
The HumanMethylation450K BeadChip (Illumina, 
Santa Clara, CA, USA) analysis was performed according 
to the manufacturer’s instructions. The default settings of 
the GenomeStudio Software’s DNA methylation module 
(Illumina) were applied to calculate the methylation levels 
of CpG sites as β-values (β = Intensity (methylated)/
intensity (methylated + unmethylated)). The data were 
further normalized using a peak correction algorithm 
embedded in the R-package Illumina Methylation Analyzer 
(IMA). To identify differentially methylated CGIs between 
tumors and paired non-tumorous lung tissues in the 
discovery LADC set, median-averaged β-differences in 
CGI-based regions were calculated based on a β-differences 
matrix in which β-values of paired non-tumorous lung 
tissues were subtracted from those of tumors; the statistical 
significance of these differences was evaluated using 
Welch’s t-test in IMA. Multiple testing corrections were 
performed using a Benjamini–Hochberg approach with 
significantly differential methylation, defined as a FDR-
adjusted P-value < 0.05. The following criteria were used 
for differentially methylated CGIs: a β-difference > 0.25 
and FDR-adjusted P-value < 0.05. Methylation data for 
the discovery cohort were deposited in the Gene Ontology 
Database (GEO) under accession number GSE83842.
Cell lines
A total of 14 LADC cell lines (A549, ABC1, 
HCC827, NCI-H358, NCI-H441, NCI-H522, NCI-H1437, 
NCI-H1650, NCI-H1975, PC3, PC14, RERF-LC-KJ, 
RERF-LC-MS, VMRC-LCD) were obtained from the 
Japanese Collection of Research Bioresources (Ibaraki, 
Japan), RIKEN BioResource Center (Tsukuba, Japan), or 
American Type Culture Collection (Manassas, VA, USA) 
and cultured in appropriate media. To analyze the effects 
of DNA demethylation and/or histone acetylation on gene 
expression, cells were treated with 1 μM 5-aza-dC for five 
days and/or 300 nM trichostatin A (TSA) for the last 12 h 
of culture. 
Primers
Primers used in this study are listed in 
Supplementary Table S4.
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed using specific primer 
sets (Supplementary Table S4) and SYBR Green Master 
Mix (Applied Biosystems, Waltham, MA, USA) as 
described elsewhere [22], or TaqMan kits (Supplementary 
Table S4) according to the manufacturer’s instructions. 
GAPDH mRNA levels were used as internal controls for 
normalization.
Processing of the TCGA data set
Available RNA-seq data (IlluminaHiSeq_RNASeqV2 
Level 3) and Infinium HumanMethylation450K data 
(Level 1) for clinical LADC specimens with clinical 
annotations were downloaded from TCGA Research 
Network (http://cancergenome.nih.gov). Gene expression 
data and DNA methylation data were available for 58 
and 29 paired tumor/non-tumorous LADC sample sets, 
respectively; both types of data without outliers were 
available for 17 sets. The DESeq2 package was applied to 
raw RSEM data to perform data normalization and evaluate 
the differential expression status of each transcript between 
tumors and non-tumorous tissues [23]. 
To evaluate CGI methylation statuses, IDAT files were 
preprocessed using the R-package IMA, and the methylation 
level of each CG site was calculated as described above. We 
computed the differential gene expression and methylation 
statuses between tumors and paired non-tumorous tissues 
and evaluated statistical significance using a paired t-test 
with multiple testing corrections via the Benjamini–
Hochberg approach (FDR-adjusted P-value). 
Antibodies
Antibodies used in this study are listed in 
Supplementary Table S5.
Western blot analysis
Whole-cell lysate preparation and western blot 
analysis were performed as previously described [22]. 
Bisulfite pyrosequencing and bisulfite genomic 
sequencing (BGS)
Bisulfite-treated genomic DNA was amplified using 
a set of primers designed with PyroMark Assay Design 
Software (version 2.0.01.15; Qiagen, Valencia, CA, USA; 
Supplementary Table S4). PCR product pyrosequencing 
and methylation quantification were performed on a 
PyroMark 24 Pyrosequencing System, version 2.0.6 
(Qiagen) with sequencing primers according to the 
manufacturer’s instructions. For BGS, bisulfite-treated 
genomic DNA were amplified, subcloned, and sequenced 
as described previously [5].
Promoter reporter assay
Six DNA fragments around the TRIM58 CGI were 
obtained via PCR with specific primer sets (Supplementary 
Table S4) and subsequently ligated into the pGL3-Basic 
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vector (Promega, Madison, WI, USA). A promoter 
reporter assay was performed using reporter constructs as 
described previously [5].
Immunohistochemical staining
Paraffin-embedded sections (thickness, 4 µm) were 
subjected to IHC staining using specific antibodies for 
each protein (Supplementary Table S5) and the Envision 
system (ChemMate Envision kit; Dako, Glostrup, 
Denmark) according to the manufacturer’s instructions.. 
Antigen retrieval was performed by heating dewaxed and 
dehydrated sections in Dako Real Target Retrieval Solution, 
pH 9 (DAKO, Glostrup, Denmark) at 98°C for 30 min. 
Fluorescent immunocytochemical staining 
Cells cultured on chamber slides were fixed, 
permeabilized, and stained using specific primary 
antibodies and fluorescently labeled secondary antibodies 
(Supplementary Table S5) as described elsewhere 
[22]. Stained cells were observed under a fluorescence 
microscope (LSM510; Carl Zeiss, Oberkochen, Germany).
Expression plasmid construction
The full coding sequence of human TRIM58 
(NM_015431) was amplified via PCR (Supplementary 
Table S4) using cDNA prepared from normal lung RNA 
(Takara, Shiga, Japan). This coding sequence was then 
cloned into the mammalian expression vector pCMV-3Tag1A 
(Stratagene, La Jolla, CA, USA) with the intent to append 
the FLAG epitope to the NH2 terminus of TRIM58. The 
product was amplified by PCR (Supplementary Table S4) and 
cloned into the retroviral vector pMXs-Neo (Cell Biolabs, 
San Diego, CA, USA). pTRIM58-WT-FLAG harboring the 
H33A mutation (pTRIM58-Mut-FLAG) was generated via 
site-directed mutagenesis (Supplementary Table S4) with a 
KOD -plus- Mutagenesis Kit (TOYOBO, Osaka, Japan). 
Transient transfection experiments
A control plasmid (pCMV-3Tag1A), pTRIM58-
WT-FLAG, and pTRIM58-Mut-FLAG were transfected 
separately into LADC cell lines or HEK293 cells using 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, 
USA).
Ubiquitin assay
HEK293T cells at < 80% confluence were co-
transfected with a MYC-tagged ubiquitin-expressing 
plasmid and either a control plasmid (pCMV-3Tag1A), 
pTRIM58-WT-FLAG, or pTRIM58-Mut-FLAG for 48 h. 
Cells were detached by scraping in 500 μL of RIPA lysis 
buffer and lysed on ice for 10 min. The lysates were then 
centrifuged at 14,000 rpm and 4°C for 10 min, after which 
the supernatants (40 μg protein) were incubated for 1 h at 
room temperature with 20 μL of a 50% (v/v) suspension 
of Anti-FLAG M2 Agarose Affinity Gel (Sigma, St. 
Louis, MO, USA). Proteins bound to the gel were pulled 
down and assayed by western blotting with an anti-MYC 
antibody, as described above.
Stable transfection experiments 
To establish LADC cell lines that would stably 
overexpress wild-type or mutant TRIM58 protein, 
cells were infected with each TRIM58-expressing 
retrovirus and selected by treatment with 0.5 mg/mL 
G418 for four weeks. Control cells were obtained using 
retroviruses generated from an empty pMXs-Neo vector 
(mock) and packaged in PLAT-A cells. Clones were 
subsequently isolated, subcultured, and tested for TRIM58 
overexpression by western blotting and FIC.
Cell proliferation and cell cycle analyses
For colony formation assays, cells were transiently 
transfected with either mock-, pTRIM58-WT-FLAG-, or 
pTRIM58-Mut-FLAG-expressing plasmids (1,000 cells/
well), plated in 6-well plates, and treated with 0.5 mg/mL 
G418 for two weeks. The expression of each TRIM58 
protein variant was confirmed 48 h after transfection by 
western blotting. The colonies in each well were stained 
with crystal violet to allow quantification.
Cell growth was assessed at the indicated time after 
cell seeding (1 × 104 cells/96-well plate) using a water-
soluble tetrazolium (WST) salt assay (Cell Counting 
Kit-8; Dojindo, Mashikimachi, Japan) according to the 
manufacturer’s instructions. The results are expressed as 
the mean absolute absorbance at the indicated time divided 
by the mean absolute absorbance of each sample cultured 
for 24 h after seeding. Cell cycle was evaluated by FACS 
as described elsewhere [22]. Raw cell cycle analysis data 
were quantified using FlowJo software (Treestar, Ashland, 
OR, USA).
Spheroid formation assays were performed 
according to a previously detailed description [22]. The 
areas of the resulting spheroids were determined using 
ImageJ software (National Institutes of Health, Bethesda, 
MD, USA; http://imagej.nih.gov/ij/). For soft-agar colony 
formation assays, a 60-mm diameter culture dish was 
coated with 3 ml of bottom agarose mixture (RPMI-
1640/10% FBS/0.5% agarose). After the bottom layer had 
solidified, 2 ml of top agarose mixture (RPMI-1640/10% 
FBS/0.33% agarose) containing 1 × 105 cells was added 
to each well. Triplicate cultures were incubated in a 5% 
CO2/95% O2 atmosphere at 37°C. At 26 days after plating, 
the colonies were stained with 0.03% crystal violet, 
photographed, and counted.
Oncotarget2904www.impactjournals.com/oncotarget
Animal studies
The experimental use of animals described 
herein was approved by the Animal Care Committee 
of Tokushima University (approval number 13105). 
Five-week-old male severe combined immunodeficient 
(SCID) mice (CLEA Japan, Tokyo, Japan) were caged in 
groups of six and acclimated for one week. A suspension 
of cells from each stably transfected clone (2 × 106 cells) 
was prepared in Matrigel (Corning, Corning, NY, USA) 
and injected subcutaneously into the bilateral flanks of 
SCID mice. Resulting tumor sizes were measured in two 
dimensions with a caliper, and volumes were calculated 
using the following formula: (short diameter)2 × (long 
diameter)/2. Recipient mice were sacrificed for tumor 
weight evaluation and protein expression analyses four 
weeks after tumor injection, and the growing tumors were 
removed and fixed with formalin in phosphate-buffered 
saline. Fixed xenografts were sectioned and subjected 
to IHC with antibodies specific for FLAG or Ki-67 
(Supplementary Table S5). 
Expression array analysis and GO and pathway 
analyses of selected genes
LADC cell lines engineered to stably overexpress 
TRIM58-WT and its control counterparts were used in an 
mRNA analysis with a SuperPrint G3 Human GE 8 × 60k 
Microarray (Agilent Technologies, Santa Clara, CA, USA). 
RNA integrity was assessed using an Agilent Bioanalyzer 
2100 (Agilent Technologies). Sample preparation, slide 
hybridization, and analysis were performed according to 
the manufacturer’s standard protocols. Data were analyzed 
using Gene Spring GX13.0 (Agilent Technologies) and 
deposited to the GEO under accession number GSE85301. 
After applying a Benjamini–Hochberg multiple testing 
correction, genes expressed differentially between groups 
were identified as those with adjusted P-values < 0.05. A 
gene set comprising upregulated and downregulated genes 
with > 2-fold changes in TRIM58-WT-expressing A549 
cells relative to control counterparts was analyzed using 
a standard enrichment analysis (DAVID Bioinformatics 
Resources 6.7, https://david.ncifcrf.gov/). The enrichment 
P-value calculation was performed using a Benjamini–
Hochberg multiple testing correction.
Statistical analysis
Results are expressed as means ± standard 
deviations (SDs). Welch’s t-test or the Mann–Whitney 
U test was used for comparisons between two groups. 
The paired t-test and Wilcoxon signed-rank test were 
used for comparisons between paired samples when the 
data were and were not normally distributed, respectively. 
Multiple group comparisons were conducted using a 
one-way analysis of variance followed by Dunnett’s 
post-hoc test or a Kruskal–Wallis analysis of variance 
followed by the Steel–Dwass post-hoc test. The relation 
between continuous variables was investigated by means 
of Pearson’s correlation coefficient. Differences were 
assessed with a two-sided test and considered significant 
at a P-value of < 0.05. Statistical analyses were performed 
using R 3.2.2 (R Project for Statistical Computing, Vienna, 
Austria).
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